Silexion Therapeutics Corp
SLXN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002022416
No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $42.5K in total; no superinvestor holds it.
Other share classesSLXNW
Q3 2024 vs. Q2 2024
How the institutions holding Silexion Therapeutics Corp changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 0 | 5 | +5 |
| Shares | 0 | 1.17M | +1.17M |
| Value | $0 | $612.8K | +$612.8K |
New holders (5)
Institutions that held Silexion Therapeutics Corp at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Wildcat Capital Management, LLC | 1,020,852 | $535.9K | 0.26% |
| HRT Financial LP | 89,970 | $47.0K | 0.00% |
| Virtu Financial LLC | 26,661 | $14.0K | 0.00% |
| Two Sigma Securities, LLC | 15,120 | $7.94K | 0.00% |
| UBS Group AG | 15,059 | $7.91K | 0.00% |
Sold out (0)
Institutions that held Silexion Therapeutics Corp at the end of Q2 2024 and filed for Q3 2024 without it.
None.